Vyome net loss widens to $719,683 in Q2 FY26; revenue falls to $26,955 - HIND News | RalliesVyome net loss widens to $719,683 in Q2 FY26; revenue falls to $26,955
H
HIND• VT-1953 regulatory update
- VT-1953 received FDA written feedback on its pre-IND package; plans include a Type C meeting before advancing a pivotal program.
Q2 FY26 results and operating expenses
- Vyome Holdings posted a net loss of $719,683 for the three months ended June 30, 2026, widening from $308,760 a year earlier.
- Revenue fell 46.03% to $26,955, driven by lower product sales and royalty income from Sun Pharma.
- Research and development expense surged more than doubled to $506,723 due to scaling regulatory consulting and CMC preparation for VT-1953.
- General and administrative costs rose 37.49% to $364,891 on higher public-company professional fees, staffing, and stock-based compensation.
